Smith & Nephew PLC
SN.: XLON (GBR)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|LL | LOCK|>FDJ? | LOCK|&bg>d!s |
Smith & Nephew Earnings: The Turnaround Started Three Years Ago and Now Bears Fruit
Smith & Nephew reported second-quarter operational revenue growth of 7%, with orthopedics and sports medicine delivering solid mid-single-digit results while advanced wound management stood out with 10% year-over-year growth.
